骨肉腫治療の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測

◆英語タイトル:Bone Cancer Treatment Market - Growth, Trends, and Forecasts (2021- 2026)
◆商品コード:MOR21MR082
◆発行会社(リサーチ会社):Mordor Intelligence
◆発行日:2021年2月
◆ページ数:120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名利用)USD4,250 ⇒換算¥488,750見積依頼/購入/質問フォーム
Team User(5名利用)USD4,750 ⇒換算¥546,250見積依頼/購入/質問フォーム
Corporate License(法人利用)USD7,500 ⇒換算¥862,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMordor Intelligence社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Mordor Intelligence社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、世界の骨肉腫治療市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、骨肉腫別(原発性骨肉腫、二次性骨肉腫)分析、治療別(化学治療、標的治療、放射線治療、手術、その他)分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の骨肉腫治療市場規模:骨肉腫別(原発性骨肉腫、二次性骨肉腫)
・世界の骨肉腫治療市場規模:治療別(化学治療、標的治療、放射線治療、手術、その他)
・世界の骨肉腫治療市場規模:地域別
・競争状況
・市場機会/将来の見通し
【レポートの概要】

The bone cancer treatment market is expected to value approximately USD 1,158 million in 2020 and USD 1,547 million by 2026, witnessing a CAGR of 4.9% during the forecast period.

During the early stages of COVID-19, a significant reduction in the number of cases treated at musculoskeletal oncology departments which have affected the number of the surgical volumes. The massive reduction in musculoskeletal oncology services may have drastic consequences for affected patients as well as for the overall market growth. However several precautionary guidelines were issued by respective government authorities to initiate the delayed or postponed bone cancer patients which can acquire safe access to treatment during the COVID-19 pandemic.

Certain factors that are driving the market growth include the increasing global burden of bone cancer and increasing government initiatives for bone cancer awareness. The incidence of bone cancer is on a steady rise and need to be wisely addressed at the earliest, to reduce the burden of bone sarcoma across the world.

According to the estimates by the American Society of Clinical Oncology, the United States was estimated to witness 3,610 new cases of bone cancer and an expected 2,060 deaths due to bone cancer in 2021. However, the chemotherapeutic drugs approved for the treatment of bone cancer do not have an effective treatment regime, as it always varies according to the prevailing conditions, and the way the patient’s body responds to the drug. The associated side effects, risks, and limitations of the treatment are limiting the growth of the global bone cancer treatment drug market.

Key Market Trends

Osteosarcoma is Expected to Hold the Largest Share in the Market Over the Forecast Period

COVID-19 pandemic has disrupted the surgical procedures, chemotherapy timings, and frequent hospital visits. In addition, the radical change in the osteosarcoma surgical plan was also observed due to the COVID-19 pandemic. In the bone cancer type segment of the bone cancer treatment market, among all primary bone cancers, osteosarcoma is expected to have the largest market size, over the forecast period.

Osteosarcoma is the most common type of cancer affecting bones, and it mostly occurs in children and young adults. Based on the cells, osteosarcoma is classified as high-, intermediate-, and low-grade. According to the American Cancer Society2019, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States every year, with about half of these occurring in children and teenagers.

Research on osteosarcoma is done at various medical centers, university hospitals, and other institutions across the world. Many advancements have taken place in the treatment of osteosarcoma in the past few decades. Osteosarcoma can be treated by surgery, radiation therapy, chemotherapy, targeted therapy drugs, etc.

Thus, research related to the bone cancer treatment market is increasing, owing to the high prevalence of osteosarcoma, globally.

North America Dominates the Market and is Expected to do Same in the Forecast Period

In North America, the COVID-19 pandemic largely affected the United States region which leads to disruptions in many surgical procedures. However, currently, the surgical procedures are being carried out with precautionary measures which will further lead to steady growth of the market.

North America currently dominates the bone cancer treatment market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that, currently, in the region, mainly in the United States, many clinical trials are underway for bone cancer therapies. Some studies are testing new chemo drugs. Researchers are also looking for new ways to use the existing approved drug portfolio. For instance, doctors are studying whether adding a bisphosphonate called zoledronic acid (Zometa) to the bone cement, which is used in filling the space left after removing a giant cell tumor, may decrease the chances of that tumor returning in that place.

Competitive Landscape

The global bone cancer treatment market is highly competitive and consists of a considerable number of significant players. All of the existing players in the global bone cancer treatment market are either legacy suppliers of treatment options, like chemotherapy and radiation therapy, or are concentrating on clinical trials for novel bone cancer approaches, including targeted therapy and immunotherapy. Companies, like Bayer AG, Amgen, Novartis AG, and Pfizer Inc., among others, are expected to hold a substantial market share in the bone cancer treatment market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

【レポートの目次】

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Bone Cancer
4.2.2 Increasing Government Initiatives for Bone Cancer Awareness
4.3 Market Restraints
4.3.1 Unavailability of Effective Treatment and Side Effects
4.3.2 High Cost of Cancer Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Bone Cancer Type
5.1.1 Primary Bone Cancer
5.1.1.1 Osteosarcoma
5.1.1.2 Chondrosarcoma
5.1.1.3 Ewing Tumour
5.1.1.4 Other Bone Cancer Types
5.1.2 Secondary Bone Cancer (Metastatic Bone Cancer)
5.2 Treatment Type
5.2.1 Chemotherapy
5.2.1.1 Doxorubicin
5.2.1.2 Cisplatin
5.2.1.3 Cyclophosphamide
5.2.1.4 Etoposide
5.2.1.5 Other Chemotherapies
5.2.2 Targeted Therapy
5.2.2.1 Denosumab
5.2.2.2 Imatinib
5.2.3 Radiation Therapy
5.2.4 Surgery
5.2.5 Other Treatments
5.3 Geography
5.3.1 North America
5.3.1.1 United States (By Cancer Type, and By Treatment Type)
5.3.1.2 Canada (By Cancer Type, and By Treatment Type)
5.3.1.3 Mexico (By Cancer Type, and By Treatment Type)
5.3.2 Europe
5.3.2.1 Germany (By Cancer Type, and By Treatment Type)
5.3.2.2 United Kingdom (By Cancer Type, and By Treatment Type)
5.3.2.3 France (By Cancer Type, and By Treatment Type)
5.3.2.4 Italy (By Cancer Type, and By Treatment Type)
5.3.2.5 Spain (By Cancer Type, and By Treatment Type)
5.3.2.6 Rest of Europe (By Cancer Type, and By Treatment Type)
5.3.3 Asia-Pacific
5.3.3.1 China (By Cancer Type, and By Treatment Type)
5.3.3.2 Japan (By Cancer Type, and By Treatment Type)
5.3.3.3 India (By Cancer Type, and By Treatment Type)
5.3.3.4 Australia (By Cancer Type, and By Treatment Type)
5.3.3.5 South Korea (By Cancer Type, and By Treatment Type)
5.3.3.6 Rest of Asia-Pacific (By Cancer Type, and By Treatment Type)
5.3.4 Middle East and Africa
5.3.4.1 GCC (By Cancer Type, and By Treatment Type)
5.3.4.2 South Africa (By Cancer Type, and By Treatment Type)
5.3.4.3 Rest of Middle East and Africa (By Cancer Type, and By Treatment Type)
5.3.5 South America
5.3.5.1 Brazil (By Cancer Type, and By Treatment Type)
5.3.5.2 Argentina (By Cancer Type, and By Treatment Type)
5.3.5.3 Rest of South America (By Cancer Type, and By Treatment Type)

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen
6.1.2 Baxter
6.1.3 Bayer AG
6.1.4 Hikma Pharmaceuticals
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Recordati Group
6.1.9 Takeda Pharmaceutical Company
6.1.10 Debiopharm
6.1.11 Eli Lilly and Company

7 MARKET OPPORTUNITIES AND FUTURE TRENDS



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨肉腫治療の世界市場2021-2026:成長・動向・新型コロナの影響・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆